Evidence map›Paper›PMID 22086303›Full record

ArticleFamilial cancer2012

Mutation and association analyses of the candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A in patients with unexplained MSH2-deficient tumors.

Nils Rahner, Felix F Brockschmidt, Verena Steinke, Philip Kahl, Tim Becker, Hans F A Vasen, Juul T Wijnen, Carli J M Tops, Elke Holinski-Feder, Marjolijn J L Ligtenberg and 9 more

Abstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Familial cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Nils RahnerInstitute of Human Genetics, BMZ, University of Bonn, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany. nils.rahner@uni-duesseldorf.de
Felix F Brockschmidt
Verena Steinke
Philip Kahl
Tim Becker
Hans F A Vasen
Juul T Wijnen
Carli J M Tops
Elke Holinski-Feder
Marjolijn J L Ligtenberg
Liesbeth Spruijt
Heike Görgens
Susanne Stemmler
Matthias Kloor
Wolfgang Dietmaier
Dutch Cancer Genetics Group
Johannes Schumacher
Markus M Nöthen
Peter Propping
University of Bonn · DERadboud University Nijmegen · NLGerman Cancer Research Center · DELeiden University · NLLeiden University Medical Center · NLTechnische Universität Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lynch syndrome (Hereditary non-polyposis colorectal cancer/HNPCC) is a cancer susceptibility syndrome which is caused by germline mutations in DNA mismatch repair (MMR) genes, in particular MLH1 and MSH2. A pathogenic germline mutation in the respective MMR gene is suggested by the finding of a loss of a mismatch repair protein in tumor tissue on immunohistochemical staining combined with an early age of onset and/or the familial occurrence of colorectal cancer. Pathogenic germline mutations are identifiable in around 60% of patients suspected of Lynch syndrome, depending on the familial occurrence. The aim of the present study was to identify novel susceptibility genes for Lynch syndrome. 64 Healthy controls and 64 Lynch syndrome patients with no pathogenic MSH2 mutation but a loss of MSH2 expression in their tumor tissue were screened for rare and disease causing germline mutations in the functional candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A. Thirty variants were identified, and these were then genotyped in an independent sample of 36 mutation negative Lynch syndrome patients and 234 controls. Since a trend towards association was observed for KAT2A, an additional set of 21 tagging SNPs was analyzed at this locus in a final case-control sample of 142 mutation negative Lynch syndrome patients and 298 controls. The mutation analysis failed to reveal any rare disease-causing mutations. No association was found at the single-marker or haplotypic level for any common disease-modifying variant. The present results suggest that neither rare nor common genetic variants in ESR1, ESR2, MAX, PCNA, or KAT2A contribute to the development of Lynch syndrome.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCase-Control StudiesColorectal Neoplasms, Hereditary NonpolyposisEstrogen Receptor alphaEstrogen Receptor betaFollow-Up StudiesHistone AcetyltransferasesHumansImmunoenzyme TechniquesMicrosatellite RepeatsMutationMutS Homolog 2 Proteinp300-CBP-Associated FactorPrognosisProliferating Cell Nuclear AntigenBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsESR1 protein, humanEstrogen Receptor alphaEstrogen Receptor betaHistone AcetyltransferasesKAT2A protein, humanMAX protein, humanMSH2 protein, humanMutS Homolog 2 Proteinp300-CBP-Associated FactorProliferating Cell Nuclear Antigen

Identifiers

PMID22086303
OpenAlexW1991823382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.